ESTTA Tracking number: **ESTTA265956**
Filing date: **02/11/2009**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding	91184464
Party	Defendant SYGNIS Pharma AG
Correspondence Address	Catherine J. Holland Knobbe, Martens, Olson & Bear LLP 2040 Main Street, 14th Floor Irvine, CA 92614 UNITED STATES efiling@kmob.com
Submission	Motion to Consolidate
Filer's Name	Catherine J. Holland
Filer's e-mail	efiling@kmob.com
Signature	/Catherine J. Holland/
Date	02/11/2009
Attachments	MOT TO CONSOLIDATE.pdf (3 pages)(91364 bytes)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

MedImmune, Inc., Opposer, v. SYGNIS Pharma AG, Applicant.	Opposition No. 91184464 Opposition No. 91184465 I hereby certify that this correspondence and all marked attachments are being electronically filed with the Trademark Trial and Appeal Board through their web site located at http://estta.uspto.gov on February 11, 2009 (Date) Catherine J. Holland

APPLICANT'S CONSENTED MOTION TO CONSOLIDATE OPPOSITION NOS. 91184464 AND 91184465

Pursuant to Trademark Trial and Appeal Board Manual of Procedure ("TBMP") §511 and Federal Rules of Civil Procedure ("FRCP") 42(a), Applicant SYGNIS Pharma AG ("SYGNIS" or "Applicant") moves the Trademark Trial and Appeal Board (the "Board") for an order consolidating Opposition No. 91184464 and Opposition No. 91184465.

These Opposition proceedings involve common questions of law and fact, similar marks, and the same parties. On June 4, 2008, Opposer, MedImmune, Inc., filed Notices of Opposition against Applicant's Application Serial Nos. 79/039,076 for the mark SYGNIS and 79/043,095 for the mark SYGNIS and Design. As grounds for both oppositions, Opposer alleged a likelihood of confusion with Opposer's U.S. Registration No. 2,248,349 for the mark SYNAGIS. These Oppositions were assigned Opposition Nos. 91184465 and 91184464.

To avoid duplicative litigation and promote judicial economy while preserving the interest of the parties in the Opposition proceedings, the above Opposition proceedings should be consolidated and treated as one proceeding[1].

Counsel for Opposer consented to Applicant's Motion to Consolidate in a telephone conversation on February 10, 2009.

Accordingly, Applicant moves that the Opposition proceedings be consolidated under TBMP 511 and FRCP 42(a) and that the Board issue an order setting new dates for discovery and trial.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/11/09

By: _____

Catherine J. Holland
Jeffrey H. Larson
2040 Main Street
Fourteenth Floor
Irvine, CA 92614
(949) 760-0404
Attorneys for Applicant,
SYGNIS Pharma AG

---

[1] Avoiding duplication of effort concerning the common issues in the case is sufficient basis for consolidation. See S. Industries Inc. v. Lamb-Weston Inc. 45 U.S.P.Q. 2d 1203,1297 (T.T.A.B.) 1997

CERTIFICATE OF SERVICE

I hereby certify that I served a copy of the foregoing **APPLICANT'S CONSENTED MOTION TO CONSOLIDATE OPPOSITION NOS. 91184464 AND 91184465** upon Opposer's counsel by agreement via e-mail on February 11, 2009.

Constance Golden
Abelman Frayne & Schwab
666 Third Avenue
New York, NY 10017
cgolden@lawabel.com

Moira Timney

6618524
021009